x

Recent Search Keywords

DAFAZIN

DAFAZIN

  • Indication
  • Mode of Action
  • Pharmacokinetics
  • Dosage
  • Packing

• Type 2 diabetes mellitus. • Heart failure with reduced ejection fraction. • Chronic kidney disease (CKD) with albuminuria.

• Selective sodium-glucose cotransporter-2 (SGLT2) inhibitor. • Reduces glucose reabsorption in kidneys, increases urinary glucose excretion.

• Absorption: Oral bioavailability ~78%, peak plasma concentration in 1-2 hours. • Metabolism: Hepatic, primarily via UGT1A9. • Elimination: Half-life of ~12.9 hours, excreted in urine and feces.

• 10 mg once daily, with or without food.

Alu-alu strip of 10*10s

Related Product

RECARB

REFORM G1

REFORM G2

REFORM G2 FORTE

REFORM G1 FORTE

GLIFAZ

INCRET M

INCRET

REFORM

REFORM SR

GLIPTIN-M

GLIPTIN